Hemophilia Market is expected to witness significant growth during the forecast period from 2018 to 30. The Hemophilia market comprises all the 3 types of Hemophilia market – A, B, C, and von Willebrand disease (VWD) market as well. The Hemophilia B market is expected to change at a CAGR of 8.9% by 2030. Increasing awareness regarding Hemophilia novel and emerging pipeline therapies, and giant pharmaceutical entrants like Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, and others shall propel the Hemophilia market during the forecast period.
DelveInsight’s Hemophilia Market Insights and Forecast report provides a thorough understanding of current treatment practices, emerging drugs, Hemophilia market share of the individual therapies, current and forecasted Hemophilia market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Hemophilia Overview
Hemophilia is an inherited rare disorder where blood doesn’t clot in a regular way because the person affected doesn’t make enough blood-clotting proteins (clotting factors). Without these factors, patients cannot stop bleeding when they are injured. Hemophilia symptoms depend on the level of clotting factors. If the clotting-factor level is mildly reduced, it might bleed only after surgery or trauma. If the deficiency is severe, one can bleed easily for seemingly no reason. Small cuts are not much dangerous but internal bleeding is very harmful to hemophiliac patients. The main concern is internal bleeding in elbows, knees, ankles, and other joints. Internal bleeding can damage the organs and tissues and can also be potentially life-threatening. Hemophilia can be further classified on the basis of clotting factors Hemophilia A is caused by factor VIII, Hemophilia B is caused by factor IX, Hemophilia C is caused by factor XI, and Von Willebrand disease, where a part of the factor VIII molecule known as von Willebrand factor or ristocetin cofactor is reduced.
Hemophilia Market Insights
The available therapeutics treatment options in the Hemophilia market landscape aim to reduce complications arising from blood accumulating in joint spaces and/or other tissues and organs. The increasing incidence of hematological and genetic disorders has been fueling the demand for new treatments such as gene therapy for Hemophilia. Favorable research and development activities by industries as well as academia are set to offer new growth dimensions for the Hemophilia market players. Other key factors such as the rising support from the government by creating awareness about Hemophilia and related drugs, rise in prevalent population of Hemophilia, expected entry of premium price assets such as gene therapy, siRNA, bispecific antibodies, and expected readily uptake of recently approved therapies will propel the growth of Hemophilia market in the coming years.
Also, the launch of emerging Hemophilia therapies like SIG-003, SIG-001, CB 2679d-GT, SerpinPC, AAV5-hFIX, Dalcinonacog alfa, Efanesoctocog alfa, Concizumab, Fitusiran, AMT-061, AMT-060, FLT180a, FLT210, STSP 0601, SPK-9001, SPK-8011, SPK-8016, Valrox, SB-FIX, SB-525, P-FVIII-101, STSP 0601, TQG203, OCTA101, PF-07055480, and others will significantly impact the Hemophilia market during the forecast period.
Whereas, on the other hand, the high cost of treatment, inconvenience, and scheduling barriers as well as lack of skilled healthcare professionals can serve as potential setbacks for the growth of the Hemophilia Market.
To know more about leaders in the Hemophilia market, get a snapshot of the Hemophilia Market Report
Key Players Proactively Working In the Hemophilia Market
Key pharma players working proactively in the Hemophilia therapeutic market are Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, Shire, Bayer, Roche, Biomarin Pharmaceutical, Alnylam Pharmaceuticals, HEMA Biologics, LFB Biotechnologies, Catalyst Biosciences, Opko Biologics, Spark Therapeutics, Sangamo Therapeutics, ApcinteX Ltd, uniQure, CSL Behring, Freeline Therapeutics, Centessa Pharmaceuticals, Poseida Therapeutics, Staidson Beijing BioPharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Octapharma, and others have the potential to create a significant positive shift in the Hemophilia market size.
Essential outcomes extracted from the Hemophilia Market Report
- According to the market research study by DelveInsight, the worldwide Hemophilia market is expected to grow by 2030 at a significant CAGR.
- The dynamics of the Hemophilia therapeutic market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Major Pharma giants are thoroughly working toward the development of new Hemophilia treatment therapies in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with Hemophilia.
- The main and current Hemophilia treatment is based on Replacement therapy, On-Demand, and Prophylaxis treatment. Treatment of Hemophilia includes names such as Factor Replacement Concentrates, Prophylactic Infusions such as Advate (Baxter), Xyntha (Pfizer), Recombinant Fusion Protein such as Eloctate, Plasma-Derived Factor Concentrates such as Feiba (Pfizer), MonoclateP (CSL Behring), and Hemofil-M (Baxter) and other Recombinant Factor IX Products such as BeneFIX, Rixubis, Ixinity, Alproli, x Idelvion, and Rebinyn.
- As far as recent developments in the Hemophilia pipeline are concerned, there are many clinical trials undergoing therapeutic development for e.g Valoctocogene Roxaparvovec is under development by Biomarin Pharmaceutical, which is an experimental gene therapy based on the use of adeno-associated virus (AAV) vectors.
- Concizumab is under development by Novo Nordisk which is a high-affinity monoclonal antibody. Sangamo in collaboration with Pfizer is investigating a recombinant adeno-associated virus serotype 6 vector for Hemophilia treatment.
- Apart from this, RG6357 (SPK-8011) is under development by Roche’s subsidiary Spark Therapeutics, another product Etranacogene Dezaparvovec (AMT-061) is being developed by UniQure Pharmaceuticals as gene therapy for Hemophilia. FLT180a is another experimental next-generation gene therapy for Hemophilia being developed by Freeline.
- There is a significant unmet need for new therapies that can reduce the great Hemophilia treatment burden associated with intravenous administration, the frequency of prophylactic infusions, products with an extended half-life, and the risk of developing neutralizing antibodies, or inhibitors, against replacement factors. An increase in research and development activities, the rise in demand for effective therapies among patients, and an upsurge in the prevalence of the disease are projected to fuel the growth of the Hemophilia market during the forecast period.
Scope of the Hemophilia Market Report:
- Geography Covered: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Study Period: 2018-30
- Key Hemophilia Companies: Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, Shire, Bayer, Roche, Biomarin Pharmaceutical, Alnylam Pharmaceuticals, HEMA Biologics, LFB Biotechnologies, Catalyst Biosciences, Opko Biologics, Spark Therapeutics, Sangamo Therapeutics, ApcinteX Ltd, uniQure, CSL Behring, Freeline Therapeutics, Centessa Pharmaceuticals, Poseida Therapeutics, Staidson Beijing BioPharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Octapharma, and others
- Key Hemophilia Pipeline Therapies: SIG-003, SIG-001, CB 2679d-GT, SerpinPC, AAV5-hFIX, Dalcinonacog alfa, Efanesoctocog alfa, Concizumab, Fitusiran, AMT-061, AMT-060, FLT180a, FLT210, STSP 0601, SPK-9001, SPK-8011, SPK-8016, Valrox, SB-FIX, SB-525, P-FVIII-101, STSP 0601, TQG203, OCTA101, PF-07055480, and others.
- Therapeutic Assessment: Hemophilia current marketed and emerging therapies
- Market Dynamics: Hemophilia market drivers and barriers
- Key Cross Competition
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs
- Case Studies
- KOL’s Views
- Analyst’s Views
- Market Access and Reimbursement Scenario
Learn more about the current and emerging Hemophilia treatment therapies @ Hemophilia Market Analysis
Table of Contents
| 1 | Key Insights |
| 2 | Executive Summary of Hemophilia |
| 3 | Competitive Intelligence Analysis for Hemophilia |
| 4 | Hemophilia: Market Overview at a Glance |
| 5 | Hemophilia: Disease Background and Overview |
| 6 | Hemophilia Patient Journey |
| 7 | Hemophilia Epidemiology and Patient Population |
| 8 | Hemophilia Treatment Algorithm, Current Treatment, and Medical Practices |
| 9 | Hemophilia Unmet Needs |
| 10 | Key Endpoints of Hemophilia Treatment |
| 11 | Hemophilia Marketed Products |
| 12 | Hemophilia Emerging Therapies |
| 13 | Hemophilia: Seven Major Market Analysis |
| 14 | Attribute analysis |
| 15 | 7MM: Hemophilia Market Outlook |
| 16 | Access and Reimbursement Overview of Hemophilia |
| 17 | KOL Views |
| 18 | Hemophilia Market Drivers |
| 19 | Hemophilia Market Barriers |
| 20 | Appendix |
| 21 | DelveInsight Capabilities |
| 22 | Disclaimer |
| 23 | About DelveInsight |
Learn more about the report offerings @Hemophilia Market Outlook
Related Reports
DelveInsight’s “Hemophilia A Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends, market drivers, market barriers and key companies involved such as Novo Nordisk, Shire, Sanofi, Bayer, Roche, Pfizer, Biomarin Pharmaceutical, Alnylam Pharmaceuticals, and many others.
DelveInsight’s, “Hemophilia A Pipeline Insight, 2022,” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in the Hemophilia A pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, and key companies involved such as Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, and many others.
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology, as well as the Hemophilia B market trends, market drivers, market barriers, and key companies, involved such as Novo Nordisk, Pfizer, UniQure Biopharma B.V., ApcinteX Ltd, Freeline Therapeutics, Sangamo Therapeutics, and several others.
DelveInsight’s, “Hemophilia B Pipeline Insight, 2022,” report provides comprehensive insights about companies and pipeline drugs in the Hemophilia B pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, and key companies involved such as Sigilon Therapeutics, Catalyst Biosciences, Centessa Pharmaceuticals, UniQure Biopharma, Sanofi Genzyme, and many more.
Acquired Hemophilia A Pipeline
DelveInsight’s, “Acquired Hemophilia A – Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Acquired Hemophilia A pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products and key companies involved such as Pfizer, Novo Nordisk, Hema Biologics, Hoffman-La-Roche, Takeda, and others.
Read Through Our Blog Posts
- The Evolved Gene Therapy for Hemophilia
- A Royal Disease: Hemophilia
- Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere?
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
+1(919)321-6187